Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors
نویسندگان
چکیده
منابع مشابه
Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
BACKGROUND The aim of this study was to assess the prognostic value of cancer antigen (CA) 125 and CA 72-4 in patients with ovarian borderline tumor (BOT). METHODS All women diagnosed and treated for BOT at our institution between 1981 and 2008 were included into this retrospective study (n=101). Preoperatively collected serum samples were analyzed for CA 125 (Architect, Abbott and Elecsys, R...
متن کامل[Predictive value of CA 125 in detection of ovarian cancer in pre- and postmenopausal patients].
AIM The aim of the study was to evaluate the usefulness of CA125 measurements in ovarian cancer diagnostics in pre- versus postmenopausal women. MATERIAL AND METHODS The study group consisted of 99 serum specimens of women diagnosed with ovarian cancer (28 pre- and 71 postmenopausal). The control group consisted of 86 specimens collected from women without any ovarian pathology (34 pre- and 5...
متن کاملThe Value of CA 125 and CA72-4 in Management of Patients with Epithelial Ovarian Cancer
UNLABELLED The role of the tumor markers CA125 and CA72-4 has been evaluated in the diagnosis and management of ovarian cancer. Both markers were measured in 30 patients with proven epithelial ovarian cancer, 30 patients with benign pelvic masses and 30 normal women. CA125 and CA72-4 were measured using the luminometric immunoassay and immunoradiometric assay respectively. All patients with ova...
متن کاملSerum CA 125 and ovarian cancer
of death from gynaecological cancer among women in Western countries. Epithelial ovarian cancer is responsible for 85-90% of all primary ovarian tumours. Because of the asymptomatic nature of the disease, ovarian cancer is usually not detected in the early stages and therefore many women present with advanced disease and systemic metastases. Approximately 70-80% of patients present with late st...
متن کاملHE4, CA-125, and cystic ovarian mass
To the editor: The recent publication on ‘HE4, CA-125, and cystic ovarian mass’ is very interesting [1]. Partheen et al. [1] concluded that HE4 did not outperform CA-125. Indeed, the use of two biomarkers might be expected for increased screening ability; however, the problem of the cost should be kept in mind. Incremental analysis on additional cost should be done. Based on the present report,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Chemistry and Laboratory Medicine
سال: 2009
ISSN: 1437-4331,1434-6621
DOI: 10.1515/cclm.2009.134